Viridian Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results and Host Investor Conference Call on March 10, 2022
Viridian Therapeutics, Inc. (NASDAQ: VRDN) will report its financial results for the fourth quarter and full year ended December 31, 2021, on March 10, 2022, after market close. The management will host a conference call at 4:30 p.m. ET on the same day. Interested parties can listen by dialing 1-877-407-0789 (U.S.) or 1-201-689-8562 (international) with conference ID: 13727096. The call will also be available via live webcast on the company's investor site. Viridian focuses on developing treatments for serious diseases, targeting insulin-like growth factor-1 receptor for thyroid eye disease.
- None.
- None.
WALTHAM, Mass., March 03, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced it will report its financial results from the fourth quarter and full year ended December 31, 2021, after the financial markets close on Thursday, March 10, 2022.
The Company’s management team will host a conference call at 4:30 p.m. ET on Thursday, March 10, 2022. To access the call, please dial 1-877-407-0789 in the U.S., or 1-201-689-8562 outside the U.S., and provide the conference ID number: 13727096. To access the live webcast, please visit the “Events” page in the Investors section of the Viridian Therapeutics, Inc. website. Following the live webcast, an archived version of the call will also be available on the website.
Thursday, March 10 at 4:30 p.m. ET
| Domestic: | 1-877-407-0789 |
| International: | 1-201-689-8562 |
| Conference ID: | 13727096 |
| Webcast: | Webcast Link |
About Viridian Therapeutics
Viridian Therapeutics is a biotechnology company advancing new treatments for patients suffering from serious diseases but underserved by today’s therapies. Viridian’s most advanced program, VRDN-001, is a differentiated monoclonal antibody targeting insulin-like growth factor-1 receptor (IGF-1R), a clinically and commercially validated target for the treatment of thyroid eye disease (TED). Viridian’s second product candidate, VRDN-002, is a distinct anti-IGF-1R antibody that incorporates half-life extension technology and is designed to support administration as a convenient, low-volume, subcutaneous injection. TED is a debilitating autoimmune disease that causes inflammation and fibrosis within the orbit of the eye which can cause double vision, pain, and potential blindness. Patients with severe disease often require multiple remedial surgeries to the orbit, eye muscles and eyelids. Viridian is based in Waltham, Massachusetts.
Investor and Media Contact:
John Jordan
Viridian Therapeutics
Vice President, Investor Relations
& Corporate Communications
617-272-4691
IR@viridiantherapeutics.com
FAQ
When will Viridian Therapeutics report its financial results for 2021?
What time is the conference call for Viridian Therapeutics' financial results?
How can I access the conference call for Viridian Therapeutics?
Will there be a webcast for Viridian Therapeutics' financial results?
